A randomized double-blind placebo-controlled trial of low-dose interleukin-2 in relapsing-remitting multiple sclerosis.
Céline LouapreMichelle RosenzwajgM GolseA RouxF PitoisetL AddaN TchitchekC PapeixE MaillartA UngureanuF Charbonnier-BeaupelD GalanaudJ C CorvolE VicautC LubetzkiDavid KlatzmannPublished in: Journal of neurology (2023)
ClinicalTrials.gov: NCT02424396; EU Clinical trials Register: 2014-000088-42.